Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
BUSINESS
Pfizer to Drop Avastin, Herceptin Biosimilars in Japan, Halving Portfolio
Pfizer is set to discontinue sales of its biosimilar versions of cancer drugs Avastin (bevacizumab) and Herceptin (trastuzumab) in Japan next year, reducing its follow-on biologics portfolio from four molecules to two. The company began notifying healthcare professionals of the…
To read the full story
Related Article
- Daiichi Sankyo to Transfer Avastin Biosimilar to Amgen in Japan
January 8, 2025
- Daiichi Sankyo to Discontinue Sales of Herceptin Biosimilar in November
January 17, 2024
- Pfizer Rolls Out Japan’s 1st Avastin Biosimilar
December 10, 2019
- Pfizer Launches Herceptin Biosimilar in Japan
August 23, 2019
BUSINESS
- Pfizer to Drop Avastin, Herceptin Biosimilars in Japan, Halving Portfolio
October 14, 2026
- Asahi Kasei’s Pritelivir Scores US Approval for HSV Infections
October 14, 2026
- Nitto Medic Recalls Heparinoid Lotion over Nitrosamine Impurity
October 14, 2026
- Moderna Rolls Out XFG-Updated Pediatric Spikevax in Japan
October 14, 2026
- Taiho to Take Over Haiyitan Marketing Authorization from Haihe
October 14, 2026
Japan’s plasma-derived product industry is approaching a turning point as the government prepares to step in with unprecedented support for…
The Wednesday TableShe had been on virtual calls since eight in the morning. The screen glowed. Her eyes burned. Plugged into Teams across time zones, she was digitally connected yet entirely isolated from the reality of Japan’s pharma market.She needed…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…